Our study seems to confirm that dual therapy dolutegravir/ lamivudine is not associated with an increased risk of worsening inflammatory state in antiretroviral therapy–naive persons in comparison with standard triple regimens.
Calza L, B.I. (2022). Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 91(4), 9-11 [10.1097/QAI.0000000000003077].
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir
Calza L;Bon I;Viale P
2022
Abstract
Our study seems to confirm that dual therapy dolutegravir/ lamivudine is not associated with an increased risk of worsening inflammatory state in antiretroviral therapy–naive persons in comparison with standard triple regimens.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
